AAAAAA

   
Results: 1-25 | 26-47 |
Results: 26-47/47
Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for the BRCA1/BRCA2 gene mutation in The Netherlands
Authors: Lodder, LN Frets, PG Trijsburg, RW Meijers-Heijboer, EJ Klijn, JGM Niermeijer, MF
Citation: Ln. Lodder et al., Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for the BRCA1/BRCA2 gene mutation in The Netherlands, J MED GENET, 37(11), 2000, pp. 883-884
Genetic testing and prophylactic surgery in familiar clusters of BRCA1 or BRCA2 mutation
Authors: Meijers-Heijboer, EJ Verhoog, LC Brekelmans, CTM Seynaeve, C Tilanus-Linthorst, MMA Wagner, A Dukel, L Devilee, P van den Ouweland, AMW van Geel, AN Klijn, JGM
Citation: Ej. Meijers-heijboer et al., Genetic testing and prophylactic surgery in familiar clusters of BRCA1 or BRCA2 mutation, GYNAKOLOGE, 33(10), 2000, pp. 768-769
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
Authors: Berns, EMJJ Foekens, JA Vossen, R Look, MP Devilee, P Henzen-Logmans, SC van Staveren, IL van Putten, WLJ Inganas, M Meijer-van Gelder, ME Cornelisse, C Claassen, CJC Portengen, H Bakker, B Klijn, JGM
Citation: Emjj. Berns et al., Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer, CANCER RES, 60(8), 2000, pp. 2155-2162
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
Authors: Foekens, JA Peters, HA Look, MP Portengen, H Schmitt, M Kramer, MD Brunner, N Janicke, F Meijer-van Gelder, ME Henzen-Logmans, SC van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, CANCER RES, 60(3), 2000, pp. 636-643
Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
Authors: Verhoog, LC Brekelmans, CTM Seynaeve, C Meijers-Heijboer, EJ Klijn, JGM
Citation: Lc. Verhoog et al., Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer, BR J CANC, 83(3), 2000, pp. 384-386
Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families
Authors: Peelen, T van Vliet, M Bosch, A Bignell, G Vasen, HFA Klijn, JGM Meijers-Heijboer, H Stratton, M van Ommen, GJB Cornelisse, CJ Devilee, P
Citation: T. Peelen et al., Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families, BR J CANC, 82(1), 2000, pp. 151-156
ATM-heterozygous germline mutations contribute to breast cancer-susceptibility
Authors: Broeks, A Urbanus, JHM Floore, AN Dahler, EC Klijn, JGM Rutgers, EJT Devilee, P Russell, NS van Leeuwen, FE van't Veer, LJ
Citation: A. Broeks et al., ATM-heterozygous germline mutations contribute to breast cancer-susceptibility, AM J HU GEN, 66(2), 2000, pp. 494-500
Family history of breast cancer and local recurrence after breast-conserving therapy
Authors: Brekelmans, CTM Voogd, AC Botke, G van Geel, BN Rodrigus, P Rutgers, EJT Klijn, JGM Coebergh, JW
Citation: Ctm. Brekelmans et al., Family history of breast cancer and local recurrence after breast-conserving therapy, EUR J CANC, 35(4), 1999, pp. 620-626
Breast-conserving therapy: Proteases as risk factors in relation to survival after local relapse
Authors: Meijer-van Gelder, ME Look, MP Bolt-de Vries, J Peters, HA Klijn, JGM Foekens, JA
Citation: Me. Meijer-van Gelder et al., Breast-conserving therapy: Proteases as risk factors in relation to survival after local relapse, J CL ONCOL, 17(5), 1999, pp. 1449-1457
Survival in hereditary breast cancer associated with germline mutations ofBRCA2
Authors: Verhoog, LC Brekelmans, CTM Seynaeve, C Dahmen, G van Geel, AN Bartels, CCM Tilanus-Linthorst, MMA Wagner, A Devilee, P Halley, DJJ van den Ouweland, AMW Meijers-Heijboer, EJ Klijn, JGM
Citation: Lc. Verhoog et al., Survival in hereditary breast cancer associated with germline mutations ofBRCA2, J CL ONCOL, 17(11), 1999, pp. 3396-3402
Insulin-like growth factor 1 (ICF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts
Authors: Sieuwerts, AM Klijn, JGM Foekens, JA
Citation: Am. Sieuwerts et al., Insulin-like growth factor 1 (ICF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts, MOL C ENDOC, 154(1-2), 1999, pp. 179-185
Genetic alterations in ovarian borderline tumours and ovarian carcinomas
Authors: Schuyer, M Henzen-Logmans, SC van der Burg, MEL Fieret, JH Derksen, C Look, MP Meijer-van Gelder, ME Klijn, JGM Foekens, JA Berns, EMJJ
Citation: M. Schuyer et al., Genetic alterations in ovarian borderline tumours and ovarian carcinomas, EUR J OB GY, 82(2), 1999, pp. 147-150
Breast cancer screening in high-risk women
Authors: Brekelmans, CTM Bartels, CCM Crepin, E van Geel, AN Meijers-Heijboer, H Seynaeve, C Tilanus-Linthorst, MMA Verhoog, LC Wagner, A Klijn, JGM
Citation: Ctm. Brekelmans et al., Breast cancer screening in high-risk women, DIS MARKER, 15(1-3), 1999, pp. 34-36
Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro
Authors: Sieuwerts, AM Klijn, JGM Henzen-Logmans, SC Foekens, JA
Citation: Am. Sieuwerts et al., Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro, BREAST CANC, 55(1), 1999, pp. 9-20
Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks?
Authors: Lodder, LN Frets, PG Trijsburg, RW Meijers-Heijboer, EJ Klijn, JGM Duivenvoorden, HJ Tibben, A Wagner, A van der Meer, CA Devilee, P Cornelisse, CJ Niermeijer, MF
Citation: Ln. Lodder et al., Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks?, J MED GENET, 36(12), 1999, pp. 906-913
Prognostic value of CD44 variant expression in primary breast cancer
Authors: Foekens, JA Dall, P Klijn, JGM Skroch-Angel, P Claassen, CJC Look, MP Ponta, H Van Putten, WLJ Herrlich, P Henzen-Logmans, SC
Citation: Ja. Foekens et al., Prognostic value of CD44 variant expression in primary breast cancer, INT J CANC, 84(3), 1999, pp. 209-215
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
Authors: de Witte, JH Sweep, CGJ Klijn, JGM Grebenschikov, N Peters, HA Look, MP van Tienoven, TH Heuvel, JJTM Vries, JBD Benraad, TJ Foekens, JA
Citation: Jh. De Witte et al., Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer, BR J CANC, 80(1-2), 1999, pp. 286-294
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
Authors: de Witte, JH Sweep, CGJ Klijn, JGM Grebenschikov, N Peters, HA Look, MP van Tienoven, TH Heuvel, JJTM van Putten, WLJ Benraad, TJ Foekens, JA
Citation: Jh. De Witte et al., Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients, BR J CANC, 79(7-8), 1999, pp. 1190-1198
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Authors: Foekens, JA Diamandis, EP Yu, H Look, MP Meijer-van Gelder, ME van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer, BR J CANC, 79(5-6), 1999, pp. 888-894
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810patients
Authors: Foekens, JA Look, MP Bolt-de Vries, J Meijer-van Gelder, ME van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810patients, BR J CANC, 79(2), 1999, pp. 300-307
Prognostic and predictive factors in breast cancer
Authors: Klijn, JGM Berns, EMJJ Foekens, JA
Citation: Jgm. Klijn et al., Prognostic and predictive factors in breast cancer, CONT ENDOC, 11, 1999, pp. 205-220
Uptake and distribution of doxorubicin in hormone-manipulated human breastcancer cells in vitro
Authors: Bontenbal, M Sieuwerts, AM Peters, HA van Putten, WLJ Foekens, JA Klijn, JGM
Citation: M. Bontenbal et al., Uptake and distribution of doxorubicin in hormone-manipulated human breastcancer cells in vitro, BREAST CANC, 51(2), 1998, pp. 139-148
Risultati: 1-25 | 26-47 |